深圳欣博盛生物科技有限公司

PepMix Human CMV (pp65)

The PepMix™ Human CMV (pp65) peptide pool offers a highly effective tool for studying immune responses to Human Cytomegalovirus (HCMV). The peptides included in this pool represent T-cell epitopes that are recognized by CMV-specific CD4 and CD8 T-cells across a broad range of MHC contexts (see table below). These T-cells, when activated, typically produce pro-inflammatory cytokines such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor (TNF).Pool of 138 peptides derived from a peptide scan (15mers with 11 aa overlap) through 65 kDa phosphoprotein (pp65) (Swiss-Prot ID: P06725) of Human Cytomegalovirus (HCMV) - strain AD169.PepMix™ Peptide Pool Human CMV pp65 ApplicationsThe PepMix™ Human CMV (pp65) antigen detects T-cell responsiveness to HCMV. As most people have CMV-specific T-cells recognizing HCMV pp65 the PepMix™ Human CMV (pp65) is often used as a positive control in T-cell stimulation assays. It is also useful for isolating CD4 and CD8 T-cells from PBMCs after activation. This isolation uses antibody-labeled magnetic beads. HCMV pp65-specific T-cells can be enriched through peptide stimulation and proliferation, creating T-cell lines or clones. JPT’s PepMix™ Peptide Pool Human CMV (pp65) is suitable for various cell assays needing high-quality peptides, including cytokine production-dependent assays like ELISPOT or flow cytometry, and detection of surface activation markers such as anti-CD154 or anti-CD137. Unlike non-specific controls such as as staphylococcus enterotoxin B (SEB), phorbol-12-myristate 13-acetate(PMA)/Ionomycin, or phytohemagglutinin (PHA), PepMix™ provides a T-cell receptor-dependent activation control, making it a more physiological and relevant option for peptide-based T-cell activation assays.PepMix™ Peptide Pool Human CMV pp65 Quality GradesJPT offers PepMix™ Human CMV (pp65) in several quality grades including development grade (purity >70%) suitable for most research applications, trial grade (purity >90%) adapted for experiments with higher purity requirements, especially for long-term studies where batch-to-batch consistency is required.HLA Specificty of PepMix™ Peptide Pool Human CMV pp65Peptides from the CMV pp65 protein are known to be presented by a wide range of HLA-molecules (note that some studies reported low-resolution, serologic specificities whereas others reported specific alleles). JPT can provide individual T-cell stimulating CMV-derived pp65 peptides for each mentioned allele. MHC molecules presenting peptides derived from human CMV-pp65 (see table).PepMix™ Human CMV (pp65) - SpecificationsAmount: 25 µg (approx. 15 nmol) / peptide (for stimulation of up to 2,5 x 108 cells)Purity: Development Grade: each peptide purified to > 70% (HPLC/MS) - (equivalent to an average purity of 85%)Delivery Format: Freeze-dried in glass vialApplication(s): T-cell ImmunityCondition(s)/Topic(s): Control, Opportunistic infections, Cytomegalovirus disease, InfectionStandard Delivery Time: 2-5 daysApplications of PepMix™ Human CMV (pp65) Detection and Functional AnalysisThe PepMix™ Human CMV (pp65) antigen is a powerful tool for:Detecting T-cell responsiveness to HCMV, a common issue during HCMV infection.Using as a positive control in T-cell stimulation assays due to its ability to stimulate CMV-specific T-cells effectively.Isolation and Enrichment of T-CellsThis product facilitates the isolation of CD4 and CD8 T-cells from PBMCs (Peripheral Blood Mononuclear Cells) through activation-dependent processes. By leveraging antibody-labeled magnetic beads, HCMV pp65-specific T-cells can be enriched and expanded, enabling the creation of T-cell lines or clones for in-depth studies.Advanced ApplicationsJPT’s PepMix™ Human CMV (pp65) is ideal for high-quality cell assays such as:Cytokine production-dependent assays, including ELISPOT and flow cytometry.Detection of surface activation markers such as anti-CD154 or anti-CD137.Unlike non-specific controls like staphylococcus enterotoxin B (SEB) or phytohemagglutinin (PHA), the PepMix™ pool ensures T-cell receptor-dependent activation, providing a more physiological and reliable solution for peptide-based T-cell activation assays.Visit our webpage for more information on Peptide Tools to Study CMV. Custom Human CMV pp65 Peptides & PoolsAre you interested in your own custom PepMix or individual HLA specific Peptides? Choose your sequence, amount, purity and pool format. We will assist you along the way.Custom PepMix Peptide PoolsCustom Peptide SynthesisAbout PepMix™ Peptide PoolsPepMix™ peptide pools are protein-spanning mixtures of overlapping peptides designed for a variety of immunological applications, including:Antigen-specific T-cell stimulation in assays like ELISPOT, ICS, cell-mediated cytotoxicity, or proliferation assays.In-vitro T-cell expansion.Dendritic cell pulsing.Immune monitoring and profiling of cellular immune responses.T-cell epitope identification.Standardization of T-cell assays.Benefits of PepMix™ Peptide PoolsGuaranteed identity and purity for each peptide.Certificate of Analysis (CoA) and HPLC-MS data provided.High batch-to-batch consistency.No false positive T-cell responses due to contaminating deletion peptides.No toxic inhibition of T-cell responses thanks to stringent peptide purification.Minimal endotoxin contamination through low bioburden processes.Animal-derived component-free (ADCF) policy.HLA-independent stimulation using antigen-spanning peptide pools.Additional Insights into HCMV and pp65Role of CMV pp65 in Viral BiologyThe pp65 protein, a critical tegument protein of HCMV, plays an essential role in:Viral replication by aiding the incorporation of viral proteins into the host cell.Modulating the host cell’s immune responses to ensure effective immune evasion.Regulating HCMV-encoded genes during viral genome expression.Research ApplicationsUnderstanding the role of cellular proteins and HCMV genes in the context of pp65 provides insights into:The mechanisms of immune evasion by HCMV.Development of antiviral strategies targeting pp65.Broader implications for studying opportunistic infections in immunocompromised individuals.